Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback